Startups
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here’s a look.
The idea is not just a flight of fancy by a brilliant mind with big dreams. It is part of a larger de-extinction strategy aimed at solving climate change.
Amicus Therapeutics is launching a next-generation genetic medicine company called Caritas Therapeutics, Inc. through a merger deal with ARYA Sciences Acquisition Corp IV.
The company aims to treat different forms of mental illness and brain disorders with its pipeline.
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.
On Tuesday, 858 Therapeutics launched with a $60 million Series A financing round under its belt.
Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
South San Francisco-based Walking Fish started the week off strong by announcing its closing of a $50 million Series A financing round on Monday.
Philip Dormitzer explained that there are plenty of reasons to be excited about the prophylactic and therapeutic potential of mRNA.
PRESS RELEASES